Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Exercise Training in Patients With Pulmonary Arterial Hypertension
In this study, the effects of kettlebell exercise training on functional capacity, dyspnea and activities of daily living in patients diagnosed with Pulmonary Arterial Hypertension (PAH) will be investigated.
- Trial name
- NCT05242380
- Testing
- Kettlebell Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Saglik Bilimleri Universitesi
Pulmonary Arterial Hypertension
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
This single center, open label, randomized, two-period, two-sequence cross-over study is designed to evaluate the relative bioavailability of a treprostinil diethanolamine 1 mg tablet in reference to treprostinil diethanolamine 1…
- Trial name
- NCT01172496
- Testing
- treprostinil diethanolamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
- Trial name
- NCT06493461
- Testing
- HS135
- Where
- 2 sites in Canada, Germany
- Volunteers
- 5 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension (PAH), Lung Fibrosis Interstitial
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung…
- Trial name
- PROMPTLY (NCT06917196)
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Pulmonary Arterial Hypertension (PAH)
Comparison of Sequential to Initial Combination Therapy in PAH
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH).
- Trial name
- ORIENTATION (NCT06968962)
- Testing
- Tadalafil, Ambrisentan, Ambrisentan mimic
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pulmonary Hypertension
Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.
- Trial name
- NCT01062282
- Testing
- Iloprost (Ventavis BAYQ6256)
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Bayer
COPD (Chronic Obstructive Pulmonary Disease), Rehabilitation
Tele-Pulmonary Rehabilitation For Patients With Chronic Lung Diseases
Pulmonary rehabilitation is a key treatment for lung diseases, but many patients struggle to attend sessions due to travel distances, physical limitations, or logistical barriers.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Rehabilitation, Bronchiectasis Adult, Pulmonary Arterial Hypertension (PAH)
- Trial name
- TELE-PRIME (NCT07666841)
- Testing
- Tele-Rehabilitation
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
- Trial name
- NCT04528056
- Testing
- Sulfasalazine, Ambrisentan
- Where
- China
- Volunteers
- 80 people
- Sponsor
- RenJi Hospital
PAH
Pulmonary Hypertension and Imatinib
The purpose of the study is to determine whether circulating molecular and cellular biomarkers are predictive of imatinib effect on pulmonary artery hypertension.
- Trial name
- NCT01092897
- Where
- 8 sites in United States
- Volunteers
- 130 people
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
- Trial name
- PALM-PAH (NCT07481981)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Sarcoidosis, Pulmonary Arterial Hypertension
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal.
- Trial name
- BOSAPAH (NCT00581607)
- Testing
- Bosentan
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Cincinnati
Cardiovascular Disease
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
This study is a Phase IV, open-label, single-arm study to assess the safety and the necessity of dose adjustment after switching to FLOLAN injection prepared with the reformulated diluent in Japanese patients with PAH who are…
- Trial name
- NCT02705807
- Testing
- FLOLAN injection with currently marketed diluent, FLOLAN injection with reformulated diluent
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50…
- Trial name
- HEMA-HTP (NCT02800941)
- Testing
- Oral anticoagulant treatment
- Where
- 4 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hypertension, Pulmonary
A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01204853
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Myocardial Dysfunction, Endothelial Dysfunction
Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH
The purpose of this study is to assess the effect of bosentan on the myocardial metabolism and the dependent endothelial coronary vasomotoricity in patients presenting a PAH.
- Trial name
- NCT02970851
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- University of Lausanne Hospitals
Pulmonary Arterial Hypertension
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other…
- Trial name
- NCT05224531
- Testing
- CS1 Administration
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension PAH
Implementing the Wuqinxi on Patients With Pulmonary Arterial Hypertension
Aims and objective: The primary objective of this study was to assess the effects of a traditional Chinese Qigong practice known as Wuqinxi on activity tolerance，negative emotions and quality of life in pulmonary arterial…
- Trial name
- PAH (NCT06454422)
- Testing
- wu qinxi
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Hypertension
Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension
Background: Prostacyclin analogues (epoprostenol, treprostinil and iloprost) induce vasodilation in advanced pulmonary arterial hypertension (PAH) but also inhibit platelets, increasing patients' bleeding risk.
- Trial name
- PAPAYA (NCT04578223)
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Warsaw